Thriva
500 GlobalFounded 2015 · 52 employees on LinkedIn · 7 known investors
Find your way into Thriva
395 people in our graph share verified history with the Thriva team — schools, employers, funds. One of them is your warm intro.
Thriva offers at-home blood testing covering over 75 health markers, with results and personalized health guidance (including integration with data from wearables like Oura). The service is aimed at consumers who want to monitor and manage their own health.
Also known as Thriva Health
Founders & leadership
Thriva was founded in 2015 by Hamish Grierson, Tom Livesey, and Eliot Brooks.
Investors · 7
Company profile
researched Aug 2026Thriva is a London-based consumer health company that sells at-home blood tests and uses the results to guide ongoing health improvement. Customers collect a blood sample at home using a postal kit, choosing from a menu of biomarkers; samples are processed and each set of results is reviewed and explained by a Thriva doctor in plain English, with benchmarks against optimal ranges and suggested priorities. Results and trends are presented in the Thriva app alongside a personalised, evidence-based action plan covering diet, exercise and supplementation, and users are encouraged to retest every three or six months to see whether changes are working.
The product spans more than 75 trackable health markers in total: over 50 blood markers grouped into lipids (11), blood sugar (HbA1c), kidney function (3), sex hormones (8), micronutrients (11), liver function (7), thyroid function (6) and inflammation (hs-CRP), plus 27 further metrics drawn from wearables, physical tests and self-ratings such as VO2 max, resting heart rate, heart rate variability, blood pressure, step count, sleep duration and quality, grip strength, dead hang, body composition measures, and stress, mood and energy ratings. Features include a healthspan dashboard, wearable and app connections that layer in passive data such as steps, sleep and cardio fitness, age- and sex-based benchmarking, goal setting, and a "Health Assistant" that answers user questions using their blood results, doctor reports, connected devices (for example Oura, Garmin, Apple Watch), goals and preferences. The company also publishes an evidence-based content library, the Health Hub, covering blood tests, nutrition, behaviour change and community health insights, and has introduced a painless one-click blood collection device for sampling from the arm.
Beyond direct-to-consumer testing, Thriva has launched personalised health plans and branded supplements and has built partnerships with hospitals and other healthcare providers; its chief executive has been described as partnering with the NHS, insurers and government bodies.
Founding story
Thriva was founded by Hamish Grierson, Eliot Brooks and Tom Livesey, with the founding dated to 2015 in one account and the company emerging publicly in 2016. Grierson has said he started the business after identifying friction in traditional blood testing, building on the premise that regular blood test kits could keep people out of hospital by surfacing problems before they escalate. Prior to Thriva he led international payments at Travelex and is a New Entrepreneurs Foundation alumnus.
Business model
Thriva sells at-home blood test kits and app-based interpretation directly to consumers, predominantly on a recurring subscription basis in which a new kit is dispatched every three months; the company has reported that around 95% of customers are subscribers. Testing starts from under £100, and in 2019 most subscribers were reported to pay £24–£69 per quarterly kit. Adjacent revenue lines include Thriva-branded and, prospectively, personalised supplements, personalised health plans, and business-to-business work with hospitals and other healthcare providers.
Recurring subscription fees for periodic at-home blood test kits and accompanying app-based results, insights and action plans, supplemented by one-off test purchases, supplement sales and partnerships with healthcare providers.
Traction
Thriva reported turnover of £2.2m in 2018 and said it was on track for close to £5m of revenue in 2019. It had posted and processed more than 100,000 at-home blood tests by August 2019 and more than 115,000 by May 2020, with a 2025 event description citing over 2 million home blood tests processed. The company reported 76% of users improving at least one biomarker between tests and roughly 100% year-on-year growth as of 2020, when its team numbered 50 people. Its website cites an "Excellent" rating based on 3,178 reviews.
Latest developments
Current product features include a healthspan dashboard spanning blood, wearable and physical-test metrics, connections to devices and apps such as Oura, Garmin and Apple Watch, cohort benchmarking, goal setting, a new one-click painless blood collection device, and the Health Assistant, which answers user health questions using their own blood results, doctor reports, wearable data and goals. Thriva now markets more than 75 trackable health markers with pricing starting under £100 and publishes research-oriented content including a Year in Health Report 2025.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Thriva has been described as the UK's leading at-home blood-testing platform and a European leader in the category, and as of 2020 claimed roughly 100% year-on-year growth. Its founder positions the company as a longitudinal consumer health relationship rather than a testing business, distinguishing it from other at-home testing providers, and has noted that the collapse of Theranos affected investor sentiment toward blood-testing startups more than consumer demand. The consumer preventative-health niche sits between healthcare and consumer investment theses, which the founder cited as a fundraising challenge.
Rather than selling one-off diagnostics, Thriva emphasises repeat, longitudinal testing on a subscription basis, arguing that trend data improves sensitivity and specificity and enables earlier detection. Every result set is reviewed and explained by an in-house doctor, results are benchmarked and combined with wearable and physical-test data in a single dashboard, and interpretation is converted into specific lifestyle, nutrition and supplement actions with follow-up testing to measure impact. The founder has framed personalisation — understanding each user's goals and journey — as the core focus of product development.", "go_to_market">
Technology
The service combines postal at-home blood sample collection, including a one-click device for painless collection from the arm, with laboratory analysis of more than 50 blood biomarkers. Software layers include the Thriva app, which visualises results and trends, a healthspan dashboard, integrations with wearables and health apps (Oura, Garmin, Apple Watch and others) to import passive metrics such as steps, sleep and heart rate, benchmarking against age and sex cohorts, goal tracking, and an AI-style "Health Assistant" that generates individualised answers from a user's blood results, doctor reports, connected device data, goals and preferences. Clinical review by Thriva doctors sits over the data to produce written interpretation and recommendations.
Go-to-market
Consumers who want to monitor and proactively manage their own health rather than patients with diagnosed chronic conditions; the company has said 95% of customers buy out of curiosity about staying well, with use cases including fertility, athletic performance and preventative screening. It also serves institutional partners such as hospitals and other healthcare providers.
Geography
Headquartered in London, United Kingdom, close to St Bartholomew's Hospital, serving customers in the UK via postal test kits; pricing is quoted in pounds sterling.
History
After launching at-home blood testing in 2015–2016, Thriva raised a £6m Series A in 2019, taking total funding to £7.5m at that point, and added a £4m extension from Target Global in May 2020, bringing cumulative funding to £11m. Around 2019 it launched a beta range of Thriva-branded supplements and shifted product development toward personalisation; by 2020 it had introduced personalised health plans and scaled partnerships with hospitals and healthcare providers. The team grew to 50 people in London by May 2020. Later product development added wearable integrations, a healthspan dashboard, benchmarking, a one-click blood collection device and a personalised Health Assistant.
Risks & controversies
Thriva's founder has said investor scepticism following the collapse of Theranos made fundraising harder for blood-testing startups, and that the consumer preventative-health category did not fit existing healthcare or consumer investment theses. He also identified a core commercial risk in consumer behaviour: people accept preventative health in principle but often fail to act, and cautioned that test-driven businesses can over-recommend interventions such as oral supplements where they are unlikely to resolve a deficiency.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Thriva went on to found or lead other companies.
Timeline · 5
launches, deals, and filingsThriva's site markets a new painless one-click blood collection device for sampling from the arm and a Health Assistant that generates personalised guidance from blood results, doctor reports, connected wearables and user goals.
Thriva secured a £4m extension to its Series A from Berlin-based Target Global, via the firm's Early Stage Fund II, topping up the £6m Series A raised in 2019 and taking total funding to £11m. Existing investors included Guinness Asset Management and Pembroke VCT.
Alongside its 2020 funding, Thriva reported launching personalised health plans and supplements and scaling up partnerships with hospitals and other healthcare providers.
Investors put £6m into Thriva's Series A round, bringing total funding raised at that point to £7.5m.
Thriva launched a beta version of its own branded supplements around early 2019, with an ambition to offer personalised supplements later.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Companies House · registry record
View on Companies House ↗- Registered name
- THRIVA LIMITED
- Company number
- 09828160
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 16 Oct 2015
- Registered office
- Office3.02, 3rd Floor, White Collar Factory, Old Street Yard, London, EC1Y 8AF
- Nature of business (SIC)
- 62090 — Other information technology service activities
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 15 Oct 2025 · next due 29 Oct 2026
Current officers · 3
- Hamish Grierson — director, appointed 16 Oct 2015
- Thomas James Livesey — director, appointed 7 Mar 2016
- Ajit Virk — director, appointed 6 Jul 2017
Source: Companies House public register · retrieved 30 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
▸Research sources · 8
primary sources listed
- Thrivathriva.co · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Thriva do?
- Thriva is a UK consumer health company offering subscription at-home blood testing with doctor-reviewed results and action plans.
- Who founded Thriva?
- Thriva was founded by Hamish Grierson, Tom Livesey, Eliot Brooks in 2015.
- Who are Thriva's investors?
- Thriva's investors include 500 Global, Guinness Ventures, Pembroke VCT, Redbus Ventures, Seedcamp, Target Global, London Co-Investment Fund.